LCTX
AMEX · Biotechnology
Lineage Cell Therapeutics In
$1.53
+0.02 (+1.32%)
Open$1.52
Previous Close$1.51
Day High$1.55
Day Low$1.49
52W High$2.09
52W Low$0.43
Volume—
Avg Volume1.45M
Market Cap341.25M
P/E Ratio—
EPS$-0.28
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+2,541.8% upside
Current
$1.53
$1.53
Target
$40.42
$40.42
$29.91
$40.42 avg
$53.83
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 14.12M | 14.17M | 231.61M |
| Net Income | -61,581,109 | -55,606,499 | -65,233,876 |
| Profit Margin | -436.5% | -414.7% | -28.2% |
| EBITDA | -69,588,214 | -66,327,684 | -95,106,936 |
| Free Cash Flow | — | — | -33,113,271 |
| Rev Growth | -0.3% | -0.3% | -6.2% |
| Debt/Equity | 0.00 | 0.00 | 0.70 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |